BiotechTube

Ceftobiprole

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 15/100
15
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ventilator Associated Pneumonia

Conditions

Ventilator Associated Pneumonia

Trial Timeline

Oct 1, 2008 → Nov 1, 2009

NCT ID
NCT00771719

About Ceftobiprole

Ceftobiprole is a phase 1 stage product being developed by Basilea Pharmaceutica for Ventilator Associated Pneumonia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00771719. Target conditions include Ventilator Associated Pneumonia.

What happened to similar drugs?

2 of 4 similar drugs in Ventilator Associated Pneumonia were approved

Approved (2) Terminated (2) Active (0)
❌Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
❌Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3
✅Imipenem + ImipenemMerckApproved
✅Vancomycin + LinezolidPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT00965042Phase 1Completed
NCT00771524Phase 1Completed
NCT00771719Phase 1Terminated
NCT01026740Phase 1Completed

Competing Products

9 competing products in Ventilator Associated Pneumonia

See all competitors
ProductCompanyStageHype Score
Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
32
Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + DoripenemJohnson & JohnsonPhase 2
35
Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3
32
Imipenem + ImipenemMerckApproved
43
Vancomycin + LinezolidPfizerApproved
43
anidulafunginPfizerPhase 2
27
LinezolidPfizerPre-clinical
18
aerosolized vancomycin or gentamicinNektar TherapeuticsPhase 2
29
IC43 + PlaceboValneva SEPhase 2
29